Merz Pharmaceuticals
Merz Pharmaceuticals, operating as Merz Aesthetics, sells injectable biostimulators (Radiesse®), HA fillers (Belotero®), and ultrasound skin-lifting devices (Ultherapy PRIME®) to licensed physicians and aesthetic practitioners across the DACH region via a B2B2C field-sales model.
- Company typePrivate
- Founded-
- HeadquartersFrankfurt, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Merz Pharmaceuticals does
Merz Pharmaceuticals GmbH, operating commercially as Merz Aesthetics, is the aesthetics medicine division of the Merz group, headquartered in Frankfurt, Germany and focused on the DACH market via merz-aesthetics.de. The company develops, markets, and sells a portfolio of injectable regenerative biostimulators, hyaluronic acid dermal fillers, and ultrasound-based skin-lifting devices to licensed physicians and aesthetic practitioners. Its three flagship franchises are Radiesse® (a regenerative biostimulator based on calcium hydroxylapatite (CaHA) microsphere technology designed to stimulate collagen), Belotero® (a hyaluronic acid dermal filler range), and Ultherapy PRIME® (an ultrasound-based skin-lifting platform).
The underlying product technology rests on proprietary CaHA microsphere engineering, biocompatible hyaluronic acid formulations, and focused-ultrasound hardware for non-invasive lifting — each positioned as clinically validated, with Radiesse® supported by more than 25 peer-reviewed clinical studies. Merz also operates the MAX (Merz Aesthetics Exchange) educational platform and the MyMerz physician portal to support training, product information, and account management for healthcare professionals, alongside consumer-facing brand campaigns ("The Collagen Force", "Confidence is a Fine Art") and a dedicated men's aesthetic segment under "Radiesse® für Männer".
Merz operates a B2B2C commercial model: products are sold to licensed physicians and aesthetic clinics through an enterprise field-sales force at quote-based pricing set per practice, with the end consumer paying the clinic directly for procedures. A public physician-finder tool directs consumer demand back into the channel. Revenue mechanics are therefore driven by procedure volumes across a distributed physician base rather than by named enterprise contracts, with brand investment aimed at stimulating patient demand that funnels into the practitioner network.
Merz Pharmaceuticals firmographics
Firmographics- Name
- Merz Pharmaceuticals
- Legal name
- Merz Pharmaceuticals GmbH
- Website
- https://radiesse.de
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Merz Pharmaceuticals, operating as Merz Aesthetics, sells injectable biostimulators (Radiesse®), HA fillers (Belotero®), and ultrasound skin-lifting devices (Ultherapy PRIME®) to licensed physicians and aesthetic practitioners across the DACH region via a B2B2C field-sales model.
- Ownership category
- akta.pro rank
Merz Pharmaceuticals industry classification
Industry- Product category
- Medical Aesthetics
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Merz Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Frankfurt
- HQ country
- Germany
- HQ region
- Europe
Markets served
Merz Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Operations, Personnel
Revenue model
- Dermal Filler Product Sales: Merz Aesthetics generates revenue through the sale of Radiesse injectable dermal filler products to licensed physicians and aesthetic clinics. Physicians purchase the product and administer treatments to consumers, with pricing varying based on treatment areas and individual patient needs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based treatment pricing through certified physicians |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Merz Pharmaceuticals product offering
Product offeringCore offering
Merz Pharmaceuticals, operating commercially as Merz Aesthetics in Germany, develops, manufactures and sells aesthetic medicine products to licensed physicians and aesthetic clinics. Its core products are Radiesse® (a calcium hydroxylapatite-based regenerative biostimulator injectable), Belotero® (hyaluronic acid dermal fillers) and Ultherapy PRIME® (a non-invasive ultrasound skin lifting system). These are distributed exclusively through certified medical professionals who administer treatments to adult patients seeking facial rejuvenation, contouring and skin quality improvement.
Product overview
Merz Aesthetics offers a portfolio of aesthetic medicine products centered around injectables and non-invasive treatments. The core products include Radiesse® (a regenerative biostimulator using calcium hydroxylapatite for collagen stimulation), Belotero® (hyaluronic acid dermal fillers), and Ultherapy PRIME® (ultrasound-based skin lifting technology). The portfolio also includes physician support platforms such as Merz Aesthetics Exchange (MAX) and MyMerz Portal. Treatment outcomes with Radiesse® last up to 12 months or longer, and results vary based on individual factors including age, lifestyle, metabolism, and treatment area.
Differentiator
Problem solved
Functional benefit
Brands
- Belotero®: Dermal filler product line for aesthetic treatments.
- Radiesse®
- Ultherapy PRIME®
- Merz Aesthetics Exchange (MAX)
- MyMerz Portal
Products and services
- Radiesse® Regenerative biostimulator consisting of calcium hydroxylapatite (CaHA) microspheres suspended in a smooth filler gel. Provides immediate volume correction, contour definition and wrinkle reduction upon injection while stimulating the body's own production of collagen and elastin for sustained skin quality improvement. Indicated for jawline, cheeks, nasolabial folds, neck and décolletage, with results lasting up to 12 months or longer. Sold to licensed physicians and aesthetic practitioners.
- Belotero® Hyaluronic acid-based dermal filler product line used for aesthetic facial treatments. Sold to licensed physicians and aesthetic practitioners who administer it to patients for facial rejuvenation and contouring.
- Ultherapy PRIME® Non-invasive ultrasound-based treatment system for skin lifting and tightening. Used by aesthetic practitioners to deliver ultrasound energy to support non-surgical facial rejuvenation in adult patients.
Quantifiable outcome
- Treatment results last up to 12 months or longer
- +2 more outcomes
Companies that use Merz Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Merz Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Merz Pharmaceuticals partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Merz Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Teoxane: Swiss aesthetics company specializing in hyaluronic acid dermal fillers with strong European physician-channel presence; direct overlap with Merz's Belotero franchise.
- Hugel: Korea-headquartered aesthetics firm with botulinum toxin and HA filler portfolio expanding globally; competes in the same physician-administered injectable category.
- Galderma: Global aesthetics pure-play whose portfolio includes Restylane (HA filler), Sculptra (PLLA biostimulator), and Dysport — direct category competitors to Merz's Radiesse, Belotero, and injectable toxins across physician channels.
- Sinclair Pharma: Aesthetics-focused company with HA fillers, bio-stimulators, and complementary energy-based devices in Europe; comparable go-to-market through physicians and overlapping product positioning with Radiesse and Belotero.
- Croma-Pharma: Austrian aesthetics company offering HA fillers, PRP, and biostimulators through physician channels across Europe; comparable product mix and regional DACH overlap.
Emerging players
- Prollenium Medical Technologies: Canadian developer of Revanesse HA dermal fillers distributed globally through physician channels; comparable injectable filler category and physician go-to-market.
- Evolus: Aesthetics pure-play behind Jeuveau (prabotulinumtoxinA); while currently toxin-focused, it is a peer in physician-channel aesthetics marketing and patient acquisition.
- Revance Therapeutics: Aesthetics biotech with neuromodulator (Daxxify) and expanding filler/biostimulator pipeline; competes for the same physician customers and aesthetic patient demand.
- Suneva Medical: Aesthetics company marketing regenerative products (Bellafill PMMA filler, Silhouette InstaLift threads); overlaps with Radiesse in the regenerative/biostimulator narrative.
Broad incumbents
- Allergan Aesthetics (AbbVie): Aesthetics division of AbbVie and owner of Juvederm, Botox, CoolSculpting, and Latisse; competes head-to-head with Radiesse in HA/biostimulator fillers and dominates physician relationships globally.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Merz Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Merz Pharmaceuticals leadership team
Management profileNumber of profiles
Merz Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Merz Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Merz Pharmaceuticals
What does Merz Pharmaceuticals do?
Merz Pharmaceuticals, operating commercially as Merz Aesthetics in Germany, develops, manufactures and sells aesthetic medicine products to licensed physicians and aesthetic clinics. Its core products are Radiesse® (a calcium hydroxylapatite-based regenerative biostimulator injectable), Belotero® (hyaluronic acid dermal fillers) and Ultherapy PRIME® (a non-invasive ultrasound skin lifting system). These are distributed exclusively through certified medical professionals who administer treatments to adult patients seeking facial rejuvenation, contouring and skin quality improvement.
Is Merz Pharmaceuticals a public or private company?
Merz Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Merz Pharmaceuticals founded?
Merz Pharmaceuticals was founded in -1. It employs 1 to 10 people.
Where is Merz Pharmaceuticals based?
Merz Pharmaceuticals is headquartered in Frankfurt, Germany, in the Europe region.
How does Merz Pharmaceuticals make money?
One revenue line is on record: dermal Filler Product Sales.
Who are Merz Pharmaceuticals's main competitors?
Direct peers on record are Teoxane, Hugel, Galderma, Sinclair Pharma and Croma-Pharma. Emerging players are Prollenium Medical Technologies, Evolus, Revance Therapeutics and Suneva Medical. Allergan Aesthetics (AbbVie) is listed as a broad incumbent.
Does Merz Pharmaceuticals have an API?
No public API is recorded for Merz Pharmaceuticals.
What industry is Merz Pharmaceuticals in?
Merz Pharmaceuticals's product category is Medical Aesthetics. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 3391 and its SIC code is 2844.